MétaCan
Menu
← Back to cohort

Abstract 15506: Pattern of Use of Anakinra for Patients With Kawasaki Disease versus Multisystem Inflammatory Syndrome in Children Associated With COVID-19

2023· article· en· W4389958566 on OpenAlexaff
Michael A. Portman, Ashraf S. Harahsheh, Geetha Raghuveer, Balasubramanian Sundraram, Aishwarya Venkataraman, Marco Antonio Yamazaki-Naksahimada, Susan Park, Mona El Ganzoury, Audrey Dionne, Deepika Thacker, Arthur Chang, Nadine Choueiter, Elizabeth Braunlin, William B. Orr, Kimberly E. McHugh, Pedrom Farid, Cedric Manlhiot, Brian W. McCrindle

Bibliographic record

VenueCirculation · 2023
Typearticle
Languageen
FieldMedicine
TopicKawasaki Disease and Coronary Complications
Canadian institutionsHospital for Sick Children
Fundersnot available
KeywordsAnakinraMedicineKawasaki diseaseAdverse effectInternal medicinePediatricsDiseaseSurgeryArtery

Abstract

fetched live from OpenAlex

Background/Aims: Anakinra (interleukin-1 blocker) has emerged as a potential adjunctive therapy for treating resistant acute Kawasaki disease (KD) and those with evolving aneurysms, and has been used as both primary and adjunct therapy for treating Multisystem Inflammatory Syndrome in Children (MIS-C), both in the absence of randomized trials. We sought to determine patterns of use, adverse events and evidence of benefit. Methods: The International KD Registry contemporaneously enrolled 727 patients with KD (site diagnosis confirmed by AHA criteria) and 1476 with MIS-C (site diagnosis confirmed by CDC criteria) from 39 sites in 7 countries from 01/2020 to 01/2023. Data collected included demographics, clinical features and presentation, management, laboratory values, and outcomes. Results: Anakinra was used at 22 (56%) sites for 11 (1.5%) KD patients (median duration 21 days) and 257 (17.4%) MIS-C patients (8 days; 11% discharged on anakinra). For KD, anakinra was used for treatment resistance for 5 sites, evolving aneurysms 3, macrophage activation syndrome (MAS) 1 and not-specified for 2. For MIS-C, anakinra use was determined by protocol for 3 sites, on a case-by-case basis for 10, reserved for treatment failure for 3 and not-specified for 6 sites. Reported indications for use (may be multiple) included routine use for ICU patients for 34% of treated MIS-C patients, worsening/persistent lab abnormalities 28%, critical decompensation (primarily cardiac) 21%, persistent/recurrent fever 21%, treatment failure 9%, coronary artery abnormalities 8%, and cytokine storm/MAS for 4%. Adverse events in treated MIS-C patients were noted for 23 (9%) and included neutropenia in 9, transaminitis 8, injection site pain/rash 4 and one each with anemia and thrombocytopenia. Extreme patient heterogeneity and confounding by indication precluded a formal analysis of impact on outcomes, although sites reported evidence of clinical improvement relevant to reported indications for all but one patient. Conclusions: Greater anakinra use for MIS-C vs KD likely reflects greater perceived indication, primarily greater clinical and inflammatory severity. Subjective evidence of benefit and a low prevalence of adverse events suggest an ongoing role for anakinra.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.007

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.003
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.036
GPT teacher head0.278
Teacher spread0.241 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueCirculation→Same topicKawasaki Disease and Coronary Complications→French-language works237,207→